Insulet (NASDAQ: PODD - Get Free Report) and GE HealthCare Technologies (NASDAQ: GEHC - Get Free Report) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk. Volatility and Risk Insulet has a beta

Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations

Insulet jumps after Q4 EPS and revenue beat, margin expansion and record Omnipod growth power a strong 2025 finish and upbeat 2026 outlook.

Insulet Corporation (NASDAQ: PODD - Get Free Report) gapped up before the market opened on Wednesday following a better than expected earnings announcement. The stock had previously closed at $246.34, but opened at $266.00. Insulet shares last traded at $260.6720, with a volume of 732,680 shares traded. The medical instruments supplier reported $1.55 EPS for the

Insulet Corporation (PODD) Q4 2025 Earnings Call Transcript

Total Revenue: $784 million in Q4 2025, a 29% increase in constant currency.Full Year Revenue: Surpassed $2.7 billion, with approximately 30% year-over-year co

Insulet Corporation  (NASDAQ: PODD) stock is trading higher on Wednesday after the company reported better-than-expected fourth-quarter earnings and 2026 guidance.

The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Insulet (PODD) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.15 per share a year ago.

Insulet reported better-than-expected fourth-quarter results on Wednesday, on the back of strong demand for its tubeless insulin pumps that eliminate the need for daily injections.